NCT02076243View on ClinicalTrials.gov

Treatment With Nab-paclitaxel in Cutaneous SCC

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
DRUG

nab-paclitaxel

nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER